SCHEMBL4075302

SCHEMBL4075302

N#Cc1cnc(-c2ccccc2)cc1CCO

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 2/20 0.45
CDK1 P06493 1/20 0.45
NPSR1 Q6W5P4 2/20 0.44
KDM4E B2RXH2 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
ALDH1A1 P00352 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
SQOR Q9Y6N5 1/20 0.41
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
ADORA2A P29274 2/20 0.40
ADORA1 P30542 2/20 0.40
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7213782 0.79 NPSR1 (0.53) KDRNPSR1KDM4ENPC1RAB9A
SCHEMBL4069229 0.76 WNT3A (0.41) NPSR1KDM4ENPC1RAB9ARXFP1
SCHEMBL7219026 0.74 GABRG2 (0.50) NPSR1KDM4ENPC1RAB9ARXFP1
SCHEMBL4073646 0.73 CDK1 (0.36) KDRCDK1KDM4EALDH1A1L3MBTL1
SCHEMBL4072388 0.73 LDHA (0.53) KDRCDK1NPSR1KDM4ENPC1
SCHEMBL18573282 0.73 IDO1 (0.49) NPSR1KDM4ENPC1RAB9ARXFP1
SCHEMBL7259682 0.73 NPSR1 (0.54) KDRNPSR1KDM4ENPC1RAB9A
SCHEMBL536176 0.71 FFAR1 (0.44) KDRCDK1KDM4ERAB9AALDH1A1
SCHEMBL30129807 0.71 FFAR1 (0.44) KDRCDK1KDM4ERAB9AALDH1A1
SCHEMBL4064788 0.71 ADORA1 (0.51) NPSR1KDM4EALDH1A1SQORADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601736-B2 Such as 3,4-dihydro-pyrano[3,4-c]pyridine-1-on; cytokine suppressive antiinflammatory drugs; analgesics SK CHEMICALS CO., LTD. (KR) 2009-10-13 US disclosed
EP-1706412-A4 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS CO LTD (KR) 2009-03-18 EP disclosed
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same SK CHEMICALS CO., LTD. (KR) 2007-11-01 US disclosed
EP-1706412-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK Chemicals, Co., Ltd. (KR) 2006-10-04 EP disclosed
WO-2005063768-A1 NOVEL PYRIDINE DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND A PHARMACEUTICAL COMPOSITION CONTAINING THE SAME SK CHEMICALS, CO., LTD. (KR) 2005-07-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254909-A1 Novel Pyridine Derivatives, a Process for Their Preparation and a Pharmaceutical Composition Containing the Same IL5, IL1B, P2RY4 KDR 3013/4885CDK1 1399/4885NPSR1 1061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.